Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Operations Research | Costing Methods | Chronic Disease/Risk | Preferences/Values | Priority Setting/Ethics | Health Outcomes | Value of Information | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
ArticlePublication 2023Out-of-Pocket Expenditures & Financial Risks Associated with Treatment of Vaccine-Preventable Diseases in Ethiopia
This study investigates out-of-pocket (OOP) expenditures and associated catastrophic health expenditures (CHEs) for vaccine-preventable diseases …
This study investigates out-of-pocket (OOP) expenditures and associated catastrophic health expenditures (CHEs) for vaccine-preventable diseases (VPDs) in Ethiopia. Through a cross-sectional costing analysis, data on OOP direct medical and nonmedical expenditures were collected from 995 households in 54 health facilities nationwide. The study focuses on VPDs in children under 5 years for pneumonia, diarrhea, measles, and pertussis, and in children under 15 years for meningitis. Mean OOP expenditures per disease episode ranged from $5·6 to…
Costing Methods | Chronic Disease/Risk | Mathematical Models | Cost-Effectiveness Analysis | Child/Nutrition | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Costing Methods | Chronic Disease/Risk | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2020Data-Driven Management of Post-Transplant Medications
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs as a mechanism to reduce their …
Organ-transplanted patients typically receive high amounts of immunosuppressive drugs as a mechanism to reduce their risk of organ rejection. However, because of the diabetogenic effect of these drugs, this practice exposes them to a greater risk of new-onset diabetes after transplantation (NODAT), and hence, becoming insulin dependent. This study develops effective medication management strategies to address the common conundrum of balancing the risk of organ rejection versus that of NODAT. The article presents a robust…
Operations Research | Chronic Disease/Risk | Mathematical Models | Health/Medicine | North America -
ArticlePublication 2021BMI-Related Healthcare Costs in the U.S.
This paper estimates continuous body mass index (BMI) related health care expenditures using data from …
This paper estimates continuous body mass index (BMI) related health care expenditures using data from the Medical Expenditure Panel Survey (MEPS) 2011-2016, adjusting BMI for self-report bias and controlling for potential confounding between BMI and medical expenditures. Costs are reported in $US 2019. The analysis found a J-shaped curve of medical expenditures by BMI, with higher costs for females and the lowest expenditures occurring at a BMI of 20.5 for adult females and 23.5 for…
Costing Methods | Chronic Disease/Risk | Child/Nutrition | North America -
ArticlePublication 2014Step-by-Step Guideline for Disease-Specific Costing Studies in LMIC
Disease-specific costing studies can be used as input into cost-effectiveness analyses and provide important information …
Disease-specific costing studies can be used as input into cost-effectiveness analyses and provide important information for efficient resource allocation. This paper provides a step-by-step guideline for conducting disease-specific costing studies in LMICs where data availability is limited and illustrates how the guideline was applied in a costing study of cardiovascular disease prevention care in rural Nigeria. The step-by-step guideline provides practical recommendations on methods and data requirements for six sequential steps: 1) definition of the study…
Costing Methods | Chronic Disease/Risk | Health Systems | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2022Healthcare Cost of Overweight & Obesity in South Africa
This analysis estimates the healthcare cost associated with treatment of weight-related conditions from the perspective …
This analysis estimates the healthcare cost associated with treatment of weight-related conditions from the perspective of the South African public sector payer. The authors report that the total cost of overweight and obesity is estimated to be ZAR33,194 million in 2020, representing approximately 15% of government health expenditure and equivalent to 0.67% of GDP. This analysis is an example of a bottom-up gross costing approach. The study draws South African data from multiple sources to estimate…
Costing Methods | Chronic Disease/Risk | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2013Agent-Based Simulation Modelling Approach to ECEA of Health Interventions
This study develops a dynamic agent-based simulation model, the Disease Control Priorities Simulation (DCPSim) model, …
This study develops a dynamic agent-based simulation model, the Disease Control Priorities Simulation (DCPSim) model, to estimate the health and economic benefits of health interventions and policies. Authors examined two different policies that can scale up the availability of drugs for secondary prevention of acute myocardial infarction (AMI) in India: a universal public provision (UPP) that provides a drug for free at public health facilities, and a universal public finance (UPF) that provides a drug…
Dynamic Simulation | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Social Determinants | Policy/Regulation | Health/Medicine | Asia & Pacific -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Costing Methods | Chronic Disease/Risk | Health Outcomes | Evidence Synthesis | Health/Medicine | Global